Stryker Corporation $SYK Shares Sold by BNP Paribas

Key Points

• BNP Paribas reduced its Stryker stake by 90.2% in the second quarter, selling 15,825 shares and retaining 1,713 shares valued at approximately $539,000. Institutional investors collectively own 77.09% of the company.
• Analysts maintain a generally positive outlook, with Stryker carrying a consensus “Moderate Buy” rating and an average price target of $386.28. Recent ratings include JPMorgan’s “overweight” view and Wolfe Research’s downgrade to “peer perform.”
• Stryker reported quarterly EPS of $3.69, beating estimates by $0.20, while revenue rose 9.4% year over year to $6.59 billion. The company also declared a quarterly dividend of $0.88 per share, representing a 1.1% annualized yield.

BNP Paribas cut its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 90.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,713 shares of the medical technology company's stock after selling 15,825 shares during the period. BNP Paribas' holdings in Stryker were worth $539,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. VanderPol Investments L.L.C. boosted its holdings in shares of Stryker by 1.4% during the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company's stock worth $732,000 after purchasing an additional 28 shares during the period. KCM Investment Advisors LLC increased its stake in Stryker by 1.5% in the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company's stock valued at $653,000 after buying an additional 28 shares during the period. Rossby Financial LCC increased its stake in Stryker by 6.6% in the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company's stock valued at $159,000 after buying an additional 28 shares during the period. Tcfg Wealth Management LLC lifted its position in Stryker by 2.7% in the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company's stock worth $403,000 after buying an additional 29 shares in the last quarter. Finally, ICW Investment Advisors LLC boosted its stake in shares of Stryker by 0.6% during the 4th quarter. ICW Investment Advisors LLC now owns 5,096 shares of the medical technology company's stock valued at $1,791,000 after buying an additional 30 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

SYK has been the subject of several recent research reports. Sanford C. Bernstein set a $410.00 price objective on Stryker in a report on Friday, May 1st. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Stryker in a research note on Friday, July 31st. Wolfe Research lowered Stryker from an "outperform" rating to a "peer perform" rating in a report on Thursday, August 13th. JPMorgan Chase & Co. lowered their price target on Stryker from $400.00 to $350.00 and set an "overweight" rating for the company in a research note on Friday, July 31st. Finally, The Goldman Sachs Group restated a "neutral" rating and issued a $361.00 price objective on shares of Stryker in a report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, Stryker presently has a consensus rating of "Moderate Buy" and a consensus target price of $386.28.

Stryker Stock Up 2.9%

SYK opened at $331.32 on Friday. The business has a 50 day moving average of $329.10 and a 200-day moving average of $331.47. The stock has a market capitalization of $127.08 billion, a price-to-earnings ratio of 34.33, a P/E/G ratio of 2.05 and a beta of 0.76. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. During the same quarter in the previous year, the firm posted $3.13 EPS. The business's revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, sell-side analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker's dividend payout ratio (DPR) is presently 36.48%.

Insider Activity

In other Stryker news, insider Dylan Bram Crotty sold 441 shares of Stryker stock in a transaction on Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the transaction, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. The trade was a 6.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 300,000 shares of the business's stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the transaction, the director directly owned 2,301,375 shares in the company, valued at approximately $773,031,862.50. This represents a 11.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 351,267 shares of company stock worth $118,197,701. Insiders own 4.60% of the company's stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source